Wearable neuromodulation device for chronic disease treatment
Cala Health manufactures FDA-regulated wearable neuromodulation devices targeting chronic neurological conditions. The tech stack—ARM microcontrollers, Python, React/React Native, FastAPI, and PostgreSQL—reflects a medical-device company managing both embedded firmware and cloud/mobile backends. Active hiring across engineering, manufacturing, and finance, concentrated at senior/manager levels, suggests Cala is scaling toward NPI ramp and commercial launch while tackling supply-chain and manufacturing-process challenges typical of medical device scale-up.
Notable leadership hires: Marketing Director
Cala Health develops wearable bioelectronic therapies that deliver peripheral nerve stimulation for chronic disease. The company's first indication is essential tremor; additional programs are in development across neurology, cardiology, and psychiatry. Founded in 2014, Cala is a privately held company based in San Mateo, California, with 51–200 employees. Current focus includes NPI and production ramp activities, commercial launch planning, and process improvements in assembly and supply-chain cost reduction.
Cala employs ARM Cortex-M0/M3/M4 microcontrollers for embedded firmware, Python and Java for backend development, React and React Native for front-end and mobile, FastAPI for APIs, PostgreSQL and MySQL for relational databases, DynamoDB and MongoDB for NoSQL, plus Salesforce and NetSuite for commercial operations.
Cala Health is headquartered in San Mateo, California, and is privately held with 51–200 employees.
Other companies in the same industry, closest in size
Cala Health's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.